Catalyst Dossier · compiled by CeliA 🧫

Moderna, Inc. (MRNA)

Biological Products, (No Diagnostic Substances) · market cap $25.4B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Moderna, Inc. (MRNA) is a Cambridge-based mRNA therapeutics company with a broad pipeline spanning COVID-19, influenza, RSV, oncology, and rare diseases. Post-pandemic revenue has collapsed from $19.3B in 2022 to $1.9B in 2025, and the company is burning approximately $2.8B per year at net with only ~9 months of cash runway. The stock trades at ~$61 per share with a $24.2B market cap and 14.6% short interest.

The catalyst path

2026-07-30 (est.)Phase 3 · mRNA-1345imp 9/10
2026-08-01 (est.)Phase 2 · mRNA-1647imp 7/10
2026-08-01 (est.)NDA Filing · mRNA-1010imp 7/10
2026-08-07Earningsimp 5/10
2026-09-22 (est.)Phase 2 · mRNA-1405imp 7/10
2026-10-05 (est.)Phase 2 · mRNA-1189imp 7/10
2026-11-30 (est.)Phase 2 · mRNA-3745imp 7/10
2027-01-15 (est.)Phase 2 · mRNA-1647imp 7/10

Pipeline

Asset	Phase	Indication
mRNA-1283	Phase 3	COVID-19
mRNA-1010	Phase 3	Seasonal Influenza
mRNA-4157	Phase 3	Melanoma
Fluarix Tetra	Phase 3	Seasonal Influenza
mRNA-1403	Phase 3	Acute Gastroenteritis
mRNA-1273.214	Phase 3	SARS-CoV-2
Pembrolizumab	Phase 2	Advanced Solid Tumors
mRNA-1083	Phase 3	COVID-19
mRNA-1345	Phase 3	Respiratory Syncytial Virus
mRNA-1647	Phase 2	Cytomegalovirus Infection
mRNA-1030	Phase 2	Seasonal Influenza
mRNA-1769	Phase 2	Smallpox
mRNA-1608	Phase 2	Genital Herpes
mRNA-1018 for H5N8	Phase 2	Influenza
mRNA-1273	Phase 3	SARS-CoV-2
mRNA-3927	Phase 2	Propionic Acidemia
Influenza Vaccine	Phase 3	SARS-CoV-2
Fluarix®	Phase 3	Seasonal Influenza
mRNA-1073	Phase 2	SARS-CoV-2
Investigational mRNA-1273.815	Phase 3	SARS-CoV-2

Price & technical context

3-month

+59.4%

6-month

+162.3%

12-month

+163.4%

52-wk range

$22.36–$79.76

vs 50-day MA

+51.5%

vs 200-day MA

+94.0%

Realized vol

66.8%

Max drawdown

-84.9%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MRNA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.